For the Inventor, By the Inventor

Enter assignee name

Suresnes, France

Les Laboratoires Servier

USPTO Granted Patents = 296

% Expired Patents = 60.8

CIPO Patents = 57

EPO Patents = 157

Trademarks = 5

Forward Citations = 782

Loading Chart...

Loading Chart...

557 inventors (with patents filed for the assignee):

Pierre Renard (32 out of 175 patents)

Jean-Pierre Lecouve (30 out of 40 patents)

Olivier Geneste (28 out of 34 patents)

4. James Brooke Murray (27 out of 30 patents)

5. Pierre Lestage (27 out of 42 patents)

6. James Edward Paul Davidson (24 out of 27 patents)

7. Guillaume De Nanteuil (22 out of 61 patents)

8. Mark Millan (22 out of 55 patents)

9. I-Jen Chen (21 out of 27 patents)

10. Jean-Louis Peglion (20 out of 52 patents)

11. Philippe Delagrange (19 out of 42 patents)

12. Jean-Claude J Souvie (19 out of 27 patents)

13. Thierry Le Diguarher (17 out of 19 patents)

14. John Hickman (17 out of 24 patents)

15. Alain Pierre (17 out of 46 patents)

Core Competencies:

Chimeric Antigen Receptor

Anti-PD-1 Antibodies

Cancer Treatment

Monoclonal Antibodies

BCL-XL Inhibitors

FLT3 Antibodies

Combination Therapies

Tumor Inhibition

Pharmaceutical Compositions

Prognosis Prediction

MCL-1 Inhibitors

Indole Derivatives

296 patents: Sort by Forward Citations

1. 12747464 - METHOD FOR THE BIOSYNTHESIS OF DIOSMIN AND/OR HESPERIDIN IN A MICROORGANISM (2026-09-29),

2. 12649733 - 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS (2026-06-09),

3. 12643912 - Macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them (2026-06-02),

4. 12583905 - METHODS AND COMPOSITIONS FOR DOSING OF ALLOGENEIC CHIMERIC ANTIGEN RECEPTOR T CELLS (2026-03-24),

5. 12577302 - ANTI-TIM-3 ANTIBODIES AND COMPOSITIONS (2026-03-17),

6. 12570648 - 6,7-DIHYDRO-5H-PYRIDO[2,3-C]PYRIDAZINE DERIVATIVES AND RELATED COMPOUNDS AS BCL-XL PROTEIN INHIBITORS AND PRO-APOPTOTIC AGENTS FOR TREATING CANCER (2026-03-10),

7. 12467091 - Polygenic risk scores for predicting disease complications and/or response to therapy (2025-11-11),

8. 12252539 - Anti-FLT3 antibodies and compositions (2025-03-18),

9. 12221462 - Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells (2025-02-11),

10. 12129261 - Crystalline forms of a MCL-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them (2024-10-29),

11. 12077534 - Aza-heterobicyclic inhibitors of MAT2A and methods of use for treating cancer (2024-09-03),

12. 12030942 - Anti-PD-1 antibodies and compositions (2024-07-09),

13. 12012450 - Anti-NKG2A antibodies and compositions (2024-06-18),

14. 11987829 - Method for the biosynthesis of diosmin and/or hesperidin in a microorganism (2024-05-21),

15. 11939380 - Combination therapies targeting PD-1, TIM-3, and LAG-3 (2024-03-26),

Company Overview

Les Laboratoires Servier is a prominent French pharmaceutical company headquartered in Suresnes, specializing in the development and manufacturing of innovative oncology therapeutics. The organization focuses on advanced treatment modalities, including chimeric antigen receptor therapies, anti-PD-1 antibodies, and monoclonal antibodies, aimed at enhancing cancer treatment outcomes. With a commitment to research in combination therapies and tumor inhibition, Servier is dedicated to addressing unmet medical needs in oncology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

296 Patents

#1 in Suresnes

#84 in France

#3,027 in the World

Suresnes, France

Les Laboratoires Servier

Forward Citations = 782

557 inventors:

Pierre Renard (32 out of 175 patents)

Jean-Pierre Lecouve (30 out of 40 patents)

Olivier Geneste (28 out of 34 patents)

4. James Brooke Murray (27 out of 30 patents)

5. Pierre Lestage (27 out of 42 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Les Laboratoires Servier. Retrieved from https://idiyas.com/company/les-laboratoires-servier

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…